Prevention of constipation and treatment of chronic constipation. Supportive in patients with haemorrhoids and / or anal fissures, as well as in patients who are unlikely to experience strenuous exercise due to their health condition. Preparation for diagnostic and operational procedures.
Composition:
1 softcapsule contains 50 mg of sodium docusate. The preparation contains a non-crystallising liquid sorbitol.
Action:
Sodium dociaate is a surface-active compound. It works emulsifyingly and reduces the surface tension of the liquid has the borderline of the gastrointestinal epithelium and fecal masses in the large intestine, which leads to easier passage. It does not stimulate peristalsis, it facilitates defecation by increasing the volume and changing the stool consistency. It works locally in the gastrointestinal tract, the effect occurs 1-3 days after the drug is started. It is slightly absorbed from the gastrointestinal tract, which may interfere with the absorption of other preparations administered simultaneously. Excretion occurs with bile.
Contraindications:
Hypersensitivity to the components of the preparation. Nausea, vomiting. Inflammation of the appendix. Intestinal obstruction and conditions threatening intestinal obstruction (accumulation of faeces, intestinal inflammation, intestinal stenosis, peritoneal adhesions, hernia, polyps, tumors). acute pain of unknown cause in the abdomen. Bleeding from the digestive tract of unknown cause. States of dehydration. Do not use liquid paraffin, dantrone, droperidol, levometaden, digitalis, corticosteroids, Acetylsalicylic acid, Tetracycline antibiotics, diuretics.
Precautions:
Prolonged use (over 7-10 days) may result in poor performance of sodium docsate and no response to treatment. If bowel motility disorders (manifesting as changes in bowel habits, eg stool frequency and its consistency) are observed, which last longer than 2 weeks, laxatives should be used with caution because of the possibility of overlooking the intestinal cancer. The occurrence of bleeding from the rectum or weakening of natural bowel movements (manifested by a difficulty or inability to return stool) after using laxatives may indicate serious illnesses - in this case, the use of the preparation should be discontinued. Due to the sorbitol content, the product should not be used in patients with rare hereditary fructose intolerance.
Pregnancy and lactation:
The product can be used during pregnancy only in cases where, in the doctor's opinion, the benefit for the mother outweighs the potential risk to the fetus. There are no adequate data on the safety of the medicine in pregnant or breast-feeding women.
Side effects:
Rarely may occur: nausea, vomiting, bitter taste in the mouth, epigastric pain, colic pain in the intestines, diarrhea; rash.
Dosage:
Orally. Adults: 1-4 capsules / day (50 mg-200 mg). Children from 6 to 12 years: 1-2 capsules / day (50 mg-100 mg). Each dose should be taken with a full glass of water or fruit juice. The effect of the preparation occurs after 1-3 days after the first dose.
(C)
